The development and publication of this promotional content was fully funded by LEO Pharma A/S and is intended for healthcare professionals in the UK only.
Anzupgo (delgocitinib▼) is indicated for the treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate. Prescribing information for healthcare professionals in the UK can be found here. Local prescribing conditions may vary. Please refer to the prescribing information in your country of practice.▼This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Details on adverse event reporting are given at the end of this article.
